212621-63-1

Basic information

• Product Name: ETHYL 3-OXO-3-THIAZOL-2-YL-PROPIONATE
• Synonyms: Ethyl 3-oxo-3-(1,3-thiazol-2-yl)propanoate;2-Thiazolepropanoic acid, β-oxo-, ethyl ester;ETHYL 3-OXO-3-THIAZOL-2-YL-PROPIONATE;ETHYL-2-THIAZOLOYL-ACETATE;2-Thiazolepropanoic acid, beta-oxo-, ethyl ester;ethyl 3-oxo-3-(thiazol-2-yl)propanoate
• CAS NO: 212621-63-1
• Molecular Formula: C8H9NO3S
• Molecular Weight: 199.23
• Mol File: 212621-63-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 309°C at 760 mmHg
• Flash Point: 140.7°C
• Appearance: /
• Density: 1.271g/cm³
• Vapor Pressure: 0.000658mmHg at 25°C
• Refractive Index: 1.53
• PKA: 9.31±0.50(Predicted)
• CAS DataBase Reference: ETHYL 3-OXO-3-THIAZOL-2-YL-PROPIONATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-OXO-3-THIAZOL-2-YL-PROPIONATE(212621-63-1)
• EPA Substance Registry System: ETHYL 3-OXO-3-THIAZOL-2-YL-PROPIONATE(212621-63-1)

Safety Data

• Hazardous Substances Data: 212621-63-1(Hazardous Substances Data)

Usage

General Description

ETHYL 3-OXO-3-THIAZOL-2-YL-PROPIONATE is a chemical compound with the molecular formula C8H11NO3S. It is a thiazole derivative that is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. ETHYL 3-OXO-3-THIAZOL-2-YL-PROPIONATE contains a thiazole ring which is a heterocyclic aromatic ring with a five-membered sulfur and nitrogen atoms. Furthermore, the presence of an ester and a ketone group in the molecule makes it a versatile building block in organic synthesis. Its unique structure and reactivity make it a valuable chemical for the development of new drugs and other bioactive compounds.

InChI:InChI=1/C8H9NO3S/c1-2-12-7(11)5-6(10)8-9-3-4-13-8/h3-4H,2,5H2,1H3

Upstream product

• 24295-03-2 2-Acetylthiazole 
• 105-58-8 Diethyl carbonate 
• 14190-59-1 1,3-thiazole-2-carboxylic acid 
• 6148-64-7 ethyl potassium malonate 

Relevant articles and documents

Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis

Structural analysis of the essential binding elements of the oxindole-based kinase inhibitor (1) led to the identification of a novel class of heterocyclic-substituted pyrazolones. Knoevenagel condensation of a variety of activated methylene nucleophiles with indole or pyrrole carboxaldehydes provided a focused library of molecules, each containing elements of kinase pharmacophore probe. Initial screening for VEGFR-2 kinase inhibition eliminated several of the probes. Identification of an active pyrazolone motif and further optimization resulted in several highly potent VEGFR-2 inhibitors with cellular efficacy, anti-angiogenic activity ex vivo in rat aortic ring explant cultures, and oral anti-tumor efficacy in nude mice.

Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors

The histone methylation on lysine residues is one of the most studied post-translational modifications, and its aberrant states have been associated with many human diseases. In 2012, Kruidenier et al. reported GSK-J1 as a selective Jumonji H3K27 demethyl

Phenyl substituted dihydropyridine compound and uses thereof

The present invention relates to a phenyl substituted dihydropyridine compound and uses thereof, further to a pharmaceutical composition containing the compound. According to the present invention, the compound or the pharmaceutical composition can be used as mineralocorticoid receptor antagonists.

Histone demethylase JMJD3 inhibitor, preparation method and application thereof

The invention relates to compound shown as general formula (I), its stereoisomer, pharmaceutically acceptable salt, prodrug, solvate, hydrate, ester and crystal. The compound shown as general formula (I) in the invention can inhibit histone demethylase JMJD3, is used for regulating the apparent states of cells and treating a series of histone demethylase JMJD3 mediated diseases and symptoms, which specifically include lung cancer, liver cancer, primary hodgkin lymphoma, some hematologic malignant tumors, inflammation and self-immune diseases, etc.